One molecule, two names
Just as Ozempic® and Wegovy® are both semaglutide, Mounjaro® and Zepbound® are both the same active ingredient: tirzepatide, made by Eli Lilly. Mounjaro® is approved for type 2 diabetes; Zepbound® is approved for chronic weight management. Same drug, two FDA-approved uses.
What makes tirzepatide different
Tirzepatide is often called a "dual agonist." While semaglutide acts on one gut-hormone receptor (GLP-1), tirzepatide acts on two — GLP-1 and GIP. In clinical trials, that dual action was associated with especially strong results: average weight loss of roughly 20% of body weight over about 72 weeks when combined with diet and lifestyle changes.
Dosing and availability
Both products are weekly injections that start at a low dose and step up gradually to limit side effects. As with semaglutide, demand has at times outstripped supply, and compounded tirzepatide has become a more affordable, more available option for some cash-pay patients — quality permitting.
Choosing the right path
Whether brand-name Mounjaro®/Zepbound® or a compounded tirzepatide plan makes sense for you depends on eligibility, cost, insurance, and supply. A licensed provider should confirm tirzepatide is appropriate for you, set your dose, and monitor your progress — which is exactly what every program we rank includes.